9295 Results for "

ha-1 hepatocellular tumor

" in MedChemExpress (MCE) Product Catalog:
Products (9295)

9295 Results for "ha-1 hepatocellular tumor" in MCE Product Catalog:

905
905 Publications Verification
Cat. No.: HY-15763
CAS No.: 571203-78-6
Purity:  99.62%
Research Areas:  

Cancer

Erastin is a ferroptosis inducer. Erastin exhibits the mechanism of ferroptosis induction related to ROS and iron-dependent signaling. Erastin inhibits voltage-dependent anion channels (VDAC2/VDAC3) and accelerates oxidation, leading to the accumulation of endogenous reactive oxygen species. Erastin also disrupts mitochondrial permeability transition pore (mPTP) with anti-tumor activity. Furthermore, Erastin can block the uptake of cystine mediated by SLC7A11 and also spares UMRC6-EV and -C91A cells from disulfidptosis under glucose starvation [1] .
loading...
    loading...
494
494 Cited Publications
Cat. No.: HY-108232
CAS No.: 1032349-77-1
Purity:  99.72%
MK-2206 is an orally active pan-AKT inhibitor, with IC50 values of 8 nM, 12 nM and 65 nM against AKT1, AKT2 and AKT3, respectively. MK-2206 inhibits the Akt/mTOR signaling pathway and reduces the levels of downstream GSK3β and Mcl-1 via proteasomal degradation. MK-2206 induces G1-phase cell cycle arrest, apoptosis, epithelial-mesenchymal transition, fibroblast activation and extracellular matrix deposition. MK-2206 causes transient hyperglycemia and hyperinsulinemia in animals. MK-2206 can be used in research related to solid tumors, renal fibrosis and hypercholesterolemia [1] .
loading...
    loading...
494
494 Cited Publications
Cat. No.: HY-10358
CAS No.: 1032350-13-2
Purity:  99.94%
Synonyms: MK-2206 (2HCl)
MK-2206 dihydrochloride (MK-2206 2HCl) is an orally active pan-AKT inhibitor, with IC50 values of 8 nM, 12 nM and 65 nM against AKT1, AKT2 and AKT3, respectively. MK-2206 dihydrochloride inhibits the Akt/mTOR signaling pathway and reduces the levels of downstream GSK3β and Mcl-1 via proteasomal degradation. MK-2206 dihydrochloride induces G1-phase cell cycle arrest, apoptosis, epithelial-mesenchymal transition, fibroblast activation and extracellular matrix deposition. MK-2206 dihydrochloride causes transient hyperglycemia and hyperinsulinemia in animals. MK-2206 dihydrochloride can be used in research related to solid tumors, renal fibrosis and hypercholesterolemia [1] .
loading...
    loading...
317
317 Cited Publications
Cat. No.: HY-10201
CAS No.: 284461-73-0
Purity:  99.92%
Synonyms: Bay 43-9006
Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma [1] .
loading...
    loading...
317
317 Cited Publications
Cat. No.: HY-10201A
CAS No.: 475207-59-1
Purity:  99.75%
Synonyms: Bay 43-9006 tosylate
Sorafenib (Bay 43-9006) tosylate is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib tosylate induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib tosylate inhibits tumor growth and metastasis in mouse and rat models. Sorafenib tosylate can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma [1] .
loading...
    loading...
281
281 Cited Publications
Cat. No.: HY-50856
CAS No.: 941678-49-5
Synonyms: INCB18424
Research Areas:  

Cancer

Ruxolitinib (INCB18424) is an orally active and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3 [1]. Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy .
loading...
    loading...
278
278 Cited Publications
Cat. No.: HY-10227
CAS No.: 179324-69-7
Purity:  99.91%
Synonyms: PS-341; LDP-341; NSC 681239
Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM) [1] . Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs) .
loading...
    loading...
258
258 Cited Publications
Cat. No.: HY-50767
CAS No.: 571190-30-2
Synonyms: PD 0332991
Target:  

CDK

Research Areas:  

Cancer

Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma [1] .
loading...
    loading...
258
258 Cited Publications
Cat. No.: HY-50767A
CAS No.: 827022-32-2
Synonyms: PD 0332991 monohydrochloride
Target:  

CDK

Research Areas:  

Cancer

Palbociclib (PD 0332991) monohydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib monohydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma [1] .
loading...
    loading...
254
254 Cited Publications
Cat. No.: HY-A0065
CAS No.: 827022-33-3
Synonyms: PD 0332991 isethionate
Target:  

CDK

Research Areas:  

Infection Neurological Disease Cancer

Palbociclib (PD 0332991) isethionate is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib isethionate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma [1] .
loading...
    loading...
238
238 Cited Publications
Cat. No.: HY-50767C
CAS No.: 571189-11-2
Synonyms: PD-0332991 hydrochloride
Target:  

CDK

Research Areas:  

Cancer

Palbociclib (PD 0332991) hydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib hydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells. Palbociclib hydrochloride can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma [1] .
loading...
    loading...
233
233 Cited Publications
Cat. No.: HY-10484
CAS No.: 1160295-21-5
Purity:  98.58%
Synonyms: MLN4924 hydrochloride
Research Areas:  

Cancer

Pevonedistat (MLN4924) hydrochloride is a potent and selective NEDD8-activating enzyme (NAE) inhibitor, with an IC50 of 4.7 nM. Pevonedistat hydrochloride induces the deregulation of S-phase DNA synthesis, thereby disrupting protein turnover mediated by cullin-RING ligase, leading to apoptosis of human tumor cells. Pevonedistat hydrochloride suppresses the growth of human tumour xenografts in mice [1].
loading...
    loading...
233
233 Cited Publications
Cat. No.: HY-70062
CAS No.: 905579-51-3
Synonyms: MLN4924
Research Areas:  

Cancer

Pevonedistat (MLN4924) is a potent and selective NEDD8-activating enzyme (NAE) inhibitor with an IC50 of 4.7 nM. Pevonedistat induces the deregulation of S-phase DNA synthesis, thereby disrupting protein turnover mediated by cullin-RING ligase, leading to apoptosis of human tumor cells. Pevonedistat suppresses the growth of human tumour xenografts in mice [1].
loading...
    loading...
223
223 Cited Publications
Cat. No.: HY-50895A
CAS No.: 184475-55-6
Synonyms: ZD-1839 hydrochloride
Target:  

EGFR

Research Areas:  

Cancer

Gefitinib hydrochloride (ZD1839 hydrochloride) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib hydrochloride selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib hydrochloride also induces autophagy. Gefitinib hydrochloride has antitumour activity [1] .
loading...
    loading...
223
223 Cited Publications
Cat. No.: HY-50895
CAS No.: 184475-35-2
Synonyms: ZD1839
Target:  

EGFR Autophagy Apoptosis

Research Areas:  

Infection Metabolic Disease Cancer

Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer [1] .
loading...
    loading...
212
212 Cited Publications
Cat. No.: HY-17471A
CAS No.: 1115-70-4
Synonyms: 1,1-Dimethylbiguanide hydrochloride
Metformin (1,1-Dimethylbiguanide) hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo [1] .
loading...
    loading...
212
212 Cited Publications
Cat. No.: HY-B0627
CAS No.: 657-24-9
Synonyms: 1,1-Dimethylbiguanide
Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo [1] .
loading...
    loading...
208
208 Cited Publications
Cat. No.: HY-17364
CAS No.: 85622-93-1
Synonyms: NSC 362856; CCRG 81045; TMZ
Research Areas:  

Cancer

Temozolomide (NSC 362856) is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system. Temozolomide has antitumor and antiangiogenic effects [1] .
loading...
    loading...
173
173 Cited Publications
Cat. No.: HY-16749
CAS No.: 1029044-16-3
Synonyms: PLX-3397
Target:  

c-Fms c-Kit Apoptosis

Research Areas:  

Cancer

Pexidartinib (PLX-3397) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib (PLX-3397) exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib (PLX-3397) induces cell apoptosis and has anti-tumor activity. Pexidartinib has limited permeability to the blood-brain barrier, primarily through ABCB1 [1] .
loading...
    loading...
162
162 Cited Publications
Cat. No.: HY-10087A1
CAS No.: 1093851-28-5
Synonyms: ABT-263 dihydrochloride
Navitoclax dihydrochloride (ABT-263 dihydrochloride) is an orally active BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, with a Ki value of <1 nM for each target. Navitoclax dihydrochloride triggers endogenous Apoptosis and downregulates the expression of Survivin and TGFβ2. Navitoclax dihydrochloride alleviates fibrosis and induces thrombocytopenia. Navitoclax dihydrochloride exhibits anticancer activity against a variety of tumors and enhances the efficacy of chemotherapy and radiotherapy. Navitoclax dihydrochloride can be used in the research of acute lymphoblastic leukemia, ovarian cancer, and fibrotic diseases [1] .
loading...
    loading...